Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-313.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.91 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -157.78% |
| Return on Assets (Trailing 12 Months) | -83.89% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.90 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.59 |
| Inventory Turnover (Trailing 12 Months) | 0.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.16 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.54 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.38 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 94.80M |
| Free Float | 89.68M |
| Market Capitalization | $2.03B |
| Average Volume (Last 20 Days) | 3.44M |
| Beta (Past 60 Months) | 0.93 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.53% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |